40. 高安動脈炎 Takayasu arteritis Clinical trials / Disease details
臨床試験数 : 25 / 薬物数 : 50 - (DrugBank : 21) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 114
Showing 1 to 6 of 6 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2061210007 | 13/10/2021 | 28/05/2021 | A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Usteki ... | Takayasu Arteritis | Ustekinumab Participants will receive IV infusion and SC injection of ustekinumab. Placebo Participants will receive IV infusion and SC injection of matching placebo. Glucorticoid Taper Regimen Glucocorticoid will be administered orally. Ustekinumab Participants will receive IV infusion and SC injection of ustekinumab. Placebo Participants ... | Numaguchi Hirotaka | NULL | Recruiting | >= 18age old | <= 75age old | Both | 50 | Phase 3 | Japan |
| 2 | NCT04882072 (ClinicalTrials.gov) | September 15, 2021 | 10/5/2021 | A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Usteki ... | Takayasu Arteritis | Drug: Ustekinumab;Other: Placebo;Drug: Glucorticoid Taper Regimen | Janssen Pharmaceutical K.K. | NULL | Recruiting | 18 Years | 75 Years | All | 50 | Phase 3 | Japan |
| 3 | NCT04161898 (ClinicalTrials.gov) | February 4, 2020 | 12/11/2019 | A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK) A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK ... | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu) A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy ... | Takayasu Arteritis (TAK) | Drug: Upadacitinib;Drug: Placebo for Upadacitinib;Drug: Prednisolone | AbbVie | NULL | Recruiting | 18 Years | N/A | All | 54 | Phase 3 | Japan;Korea, Republic of;Turkey |
| 4 | NCT03482479 (ClinicalTrials.gov) | February 4, 2019 | 22/3/2018 | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arterit ... | Drug: Naltrexone Hydrochloride;Other: Placebo Comparator | University of Pennsylvania | NULL | Recruiting | 18 Years | N/A | All | 36 | Phase 2 | United States |
| 5 | NCT02981979 (ClinicalTrials.gov) | December 2016 | 22/11/2016 | Takayasu Arteritis Clinical Trial in China | Comparison of the Efficacy and Safety of Leflunomide Versus Placebo Combine With the Basic Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Double-blinded Trial Comparison of the Efficacy and Safety of Leflunomide Versus PlaceboCombine With the Basic Prednisone ... | Takayasu Arteritis | Drug: Leflunomide 10mg Tab;Drug: Prednisone Acetate;Drug: Placebos | Jiang lindi | NULL | Unknown status | 18 Years | 65 Years | All | 116 | N/A | China |
| 6 | JPRN-JapicCTI-142616 | 02/10/2014 | 23/07/2014 | Phase III Study of MRA-SC in Patients with Takayasu Arteritis | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients ... | Takayasu Arteritis | Intervention name : tocilizumab (MRA-SC) INN of the intervention : tocilizumab Dosage And administration of the intervention : 162mg/W, SC Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo/W, SC Intervention name : tocilizumab(MRA-SC) INN of the intervention : tocilizumab Dosage And administratio ... | Chugai Pharmaceutical Co., Ltd. | NULL | complete | 12 | BOTH | 34 | Phase 3 | Japan |